Antiangiogenesis / Angiogenesis Inhibitors

Antiangiogenesis therapy is a new form of lung cancer treatment that is currently being tested in clinical trials. Antiangiogenesis is designed to combat lung cancer by preventing angiogenesis with angiogenesis inhibitors. Here's how it works:

Angiogenesis is the formation of new blood vessels in the body. Angiogenesis is regulated by a particular set of chemicals. All cells-including cancerous cells-need to feed off these vessels so they may grow and replicate. If the cells lose access to these new blood cells (in this case, as a result of angiogenesis inhibitors), they'll shrink and eventually die. Antiangiogenesis halts the growth of new blood vessels off which cancerous tumors feed by using a combination of strong drugs called angiogenesis inhibitors. By cutting off tumors' blood supplies, angiogenesis inhibitors ultimately kill the tumors.

Although the outlook for antiangiogenesis' success is good, there are still some kinks to work out. For example, the effectiveness of antiangiogenesis in humans is not fully understood. In addition, researchers still don't know if undetected tumors can be treated with angiogenesis inhibitors, nor do they know the long-term effects of angiogenesis inhibitors on the body.

Side effects of angiogenesis inhibitors are believed to be much milder than those of other lung cancer treatments, including surgery, radiation therapy, photodynamic therapy, and chemotherapy.

To learn more about antiangiogenesis lung cancer treatment and the antiangiogenic process, contact a lung cancer attorney today.

back to top